Tags

Type your tag names separated by a space and hit enter

Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa.
Genet Med. 2013 Dec; 15(12):983-9.GM

Abstract

PURPOSE

Globotriaosylceramide concentrations were assessed as potential predictors of change from baseline after 12 months by estimated glomerular filtration rate and left-ventricular mass index using pooled data from three randomized, placebo-controlled agalsidase alfa trials and open-label extensions of patients with Fabry disease.

METHODS

Males (aged 18 years or older) with Fabry disease received agalsidase alfa (0.2 mg/kg every other week for 12 months). A backward-elimination approach evaluated potential predictors (baseline estimated glomerular filtration rate and left-ventricular mass index; age at first dose; baseline and change from baseline at 12 months of globotriaosylceramide (urine, plasma); urine protein excretion; and systolic and diastolic blood pressure). Subgroups included patients randomized to placebo or agalsidase alfa (double-blind phase), then to agalsidase alfa (open-label extensions; placebo→agalsidase alfa or agalsidase alfa→agalsidase alfa, respectively) and stage 2/3 chronic kidney disease patients.

RESULTS

Baseline estimated glomerular filtration rate, age at first dose, baseline urine globotriaosylceramide excretion, and baseline and change from baseline urine protein excretion significantly predicted change from baseline estimated glomerular filtration rate in the analysis population (N = 73; all P<0.05), although not in all subgroups. Change from baseline urine and plasma globotriaosylceramide (baseline and change from baseline) concentrations did not predict change from baseline estimated glomerular filtration rate. No predictors of left-ventricular mass index were significant.

CONCLUSION

Changes in globotriaosylceramide concentrations do not appear to be useful biomarkers for prediction of Fabry disease-related changes in estimated glomerular filtration rate or left-ventricular mass index.

Authors+Show Affiliations

Institute of Metabolic Disease, Baylor Research Institute, Dallas, Texas, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase II
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23680766

Citation

Schiffmann, Raphael, et al. "Changes in Plasma and Urine Globotriaosylceramide Levels Do Not Predict Fabry Disease Progression Over 1 Year of Agalsidase Alfa." Genetics in Medicine : Official Journal of the American College of Medical Genetics, vol. 15, no. 12, 2013, pp. 983-9.
Schiffmann R, Ries M, Blankenship D, et al. Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa. Genet Med. 2013;15(12):983-9.
Schiffmann, R., Ries, M., Blankenship, D., Nicholls, K., Mehta, A., Clarke, J. T., Steiner, R. D., Beck, M., Barshop, B. A., Rhead, W., West, M., Martin, R., Amato, D., Nair, N., & Huertas, P. (2013). Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa. Genetics in Medicine : Official Journal of the American College of Medical Genetics, 15(12), 983-9. https://doi.org/10.1038/gim.2013.56
Schiffmann R, et al. Changes in Plasma and Urine Globotriaosylceramide Levels Do Not Predict Fabry Disease Progression Over 1 Year of Agalsidase Alfa. Genet Med. 2013;15(12):983-9. PubMed PMID: 23680766.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa. AU - Schiffmann,Raphael, AU - Ries,Markus, AU - Blankenship,Derek, AU - Nicholls,Kathy, AU - Mehta,Atul, AU - Clarke,Joe T R, AU - Steiner,Robert D, AU - Beck,Michael, AU - Barshop,Bruce A, AU - Rhead,William, AU - West,Michael, AU - Martin,Rick, AU - Amato,David, AU - Nair,Nitin, AU - Huertas,Pedro, Y1 - 2013/05/16/ PY - 2013/02/12/received PY - 2013/03/26/accepted PY - 2013/5/18/entrez PY - 2013/5/18/pubmed PY - 2014/7/16/medline SP - 983 EP - 9 JF - Genetics in medicine : official journal of the American College of Medical Genetics JO - Genet. Med. VL - 15 IS - 12 N2 - PURPOSE: Globotriaosylceramide concentrations were assessed as potential predictors of change from baseline after 12 months by estimated glomerular filtration rate and left-ventricular mass index using pooled data from three randomized, placebo-controlled agalsidase alfa trials and open-label extensions of patients with Fabry disease. METHODS: Males (aged 18 years or older) with Fabry disease received agalsidase alfa (0.2 mg/kg every other week for 12 months). A backward-elimination approach evaluated potential predictors (baseline estimated glomerular filtration rate and left-ventricular mass index; age at first dose; baseline and change from baseline at 12 months of globotriaosylceramide (urine, plasma); urine protein excretion; and systolic and diastolic blood pressure). Subgroups included patients randomized to placebo or agalsidase alfa (double-blind phase), then to agalsidase alfa (open-label extensions; placebo→agalsidase alfa or agalsidase alfa→agalsidase alfa, respectively) and stage 2/3 chronic kidney disease patients. RESULTS: Baseline estimated glomerular filtration rate, age at first dose, baseline urine globotriaosylceramide excretion, and baseline and change from baseline urine protein excretion significantly predicted change from baseline estimated glomerular filtration rate in the analysis population (N = 73; all P<0.05), although not in all subgroups. Change from baseline urine and plasma globotriaosylceramide (baseline and change from baseline) concentrations did not predict change from baseline estimated glomerular filtration rate. No predictors of left-ventricular mass index were significant. CONCLUSION: Changes in globotriaosylceramide concentrations do not appear to be useful biomarkers for prediction of Fabry disease-related changes in estimated glomerular filtration rate or left-ventricular mass index. SN - 1530-0366 UR - https://www.unboundmedicine.com/medline/citation/23680766/Changes_in_plasma_and_urine_globotriaosylceramide_levels_do_not_predict_Fabry_disease_progression_over_1_year_of_agalsidase_alfa_ L2 - http://dx.doi.org/10.1038/gim.2013.56 DB - PRIME DP - Unbound Medicine ER -